The dual PI3K and mTOR inhibitor NVP-BEZ235 exhibits anti-proliferative activity and overcomes bortezomib resistance in mantle cell lymphoma cells

Leukemia Research
Areumnuri KimSeung-Sook Lee

Abstract

Mantle cell lymphoma (MCL) is one of the most difficult B-cell lymphomas to be treated. The phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathway is constitutively activated in MCL and plays a critical role in tumor growth and survival. However, single targeted agent mTOR has limited efficacy in treating MCL. Here, we investigate for the first time potential efficacy of NVP-BEZ235 (BEZ235) in treating MCL by simultaneously targeting Akt and mTOR. In this study, phosphorylated Akt and mTOR level were elevated in tissue samples from MCL patients and in MCL cell lines. We also generated bortezomib-resistant MCL cell lines and found increased phosphorylation of Akt and mTOR. Individual inhibition of PI3K or mTOR had limited anti-proliferative effects, whereas dual inhibition with BEZ235 effectively inhibited cell growth. The effect of BEZ235 was synergistic and sensitized the cells to the cytotoxic effects of conventional agents. Furthermore, BEZ235 could overcome acquired resistance to bortezomib in MCL cells and suppress the activated Akt/mTOR pathway. Therefore, these data suggest that the Akt/mTOR pathway plays a key role in the growth and survival of MCL cells and that these proteins may need to...Continue Reading

References

Dec 16, 1998·Ryōikibetsu shōkōgun shirīzu·T Hayashi, Y Nonaka
Dec 22, 1999·Annals of Hematology·P Meusers, J Hense
Mar 30, 2001·The Journal of Biological Chemistry·S FukumotoM E Lee
Mar 1, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Orion M HowardMargaret A Shipp
Feb 4, 2003·Nature Reviews. Molecular Cell Biology·Estela Jacinto, Michael N Hall
Dec 23, 2003·British Journal of Haematology·Francesco BertoniFinbarr E Cotter
Dec 16, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Michele GhielminiUNKNOWN Swiss Group for Clinical Cancer Research
Jan 15, 2005·Blood·Irene M GhobrialThomas E Witzig
Jun 29, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Thomas E WitzigScott H Kaufmann
Feb 3, 2006·Cancer Research·Kathryn E O'ReillyNeal Rosen
Jun 6, 2006·Critical Reviews in Oncology/hematology·Joshua Brody, Ranjana Advani
Jul 19, 2006·British Journal of Haematology·Reshma ShringarpureKenneth C Anderson
Sep 27, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Richard I FisherAndré Goy
Sep 19, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Robert C KaneRichard Pazdur
May 3, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·David A RizzieriFrancis J Giles
Aug 30, 2008·Current Opinion in Pharmacology·Timothy A YapPaul Workman
Feb 17, 2009·Current Oncology Reports·Joell J Gills, Phillip A Dennis
Feb 28, 2009·British Journal of Haematology·Thomas M HabermannJoseph M Tuscano
Apr 7, 2009·Molecular & Cellular Proteomics : MCP·Robert S BoydKelvin Cain
Jul 25, 2009·Nature Reviews. Cancer·Jeffrey A Engelman
Sep 3, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Amanda PsyrriTheofanis Economopoulos
Dec 8, 2009·Blood·Samar KheirallahChristine Bezombes

❮ Previous
Next ❯

Citations

Nov 21, 2013·Biomarker Research·Shuqing Lü, Jianmin Wang
Jan 5, 2013·Biochimica Et Biophysica Acta·S E KorsseW van Veelen
Aug 8, 2014·British Journal of Haematology·James S Blachly, Robert A Baiocchi
May 21, 2014·British Journal of Haematology·Toby A EyreKate Cwynarski
Jan 1, 2013·Translation·Marilena MancinoStefano Biffo
Feb 23, 2013·ISRN Hematology·Ronit Vogt Sionov
Dec 6, 2016·Expert Opinion on Drug Discovery·Richard ArkwrightQ Ping Dou
Oct 27, 2017·Cancer Metastasis Reviews·Jacqueline CloosGerrit Jansen
Feb 9, 2020·International Journal of Molecular Sciences·Chiara TarantelliFrancesco Bertoni
Mar 21, 2013·Current Treatment Options in Oncology·L Kyle Brett, Michael E Williams
May 17, 2018·Frontiers in Endocrinology·Mariah L Farrell, Michaela R Reagan

❮ Previous
Next ❯

Related Concepts

Related Feeds

BCL-2 Family Proteins

BLC-2 family proteins are a group that share the same homologous BH domain. They play many different roles including pro-survival signals, mitochondria-mediated apoptosis and removal or damaged cells. They are often regulated by phosphorylation, affecting their catalytic activity. Here is the latest research on BCL-2 family proteins.

Breast Tumorigenesis

Breast tumorigenesis involves the production or formation of tumor(s) in breast tissue. Discover the latest research on breast tumorigenesis here.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

AKT Pathway

This feed focuses on the AKT serine/threonine kinase, which is an important signaling pathway involved in processes such as glucose metabolism and cell survival.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.

Related Papers

Expert Review of Anticancer Therapy
Valérie Camara-ClayetteVincent Ribrag
Seminars in Hematology
Hanneke C Kluin-Nelemans, Jeanette K Doorduijn
Expert Opinion on Therapeutic Targets
Peter Martin, John P Leonard
© 2021 Meta ULC. All rights reserved